000303658 001__ 303658
000303658 005__ 20250820114611.0
000303658 0247_ $$2doi$$a10.1007/s00404-025-08139-8
000303658 0247_ $$2pmid$$apmid:40824530
000303658 0247_ $$2ISSN$$a0003-9128
000303658 0247_ $$2ISSN$$a0170-9925
000303658 0247_ $$2ISSN$$a0932-0067
000303658 0247_ $$2ISSN$$a1432-0711
000303658 037__ $$aDKFZ-2025-01721
000303658 041__ $$aEnglish
000303658 082__ $$a610
000303658 1001_ $$aJakob, D.$$b0
000303658 245__ $$aTreatment and survival of early non-metastatic breast cancer in men: real world data from a population-based registry.
000303658 260__ $$aHeidelberg$$bSpringer$$c2025
000303658 3367_ $$2DRIVER$$aarticle
000303658 3367_ $$2DataCite$$aOutput Types/Journal article
000303658 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755678627_25160
000303658 3367_ $$2BibTeX$$aARTICLE
000303658 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303658 3367_ $$00$$2EndNote$$aJournal Article
000303658 500__ $$aepub
000303658 520__ $$aThis study aimed to characterize a cohort of male patients with non-metastatic breast cancer, specifically focusing on tumor characteristics, treatment strategies, and determinants of overall survival.Data for this study were obtained from the Baden-Württemberg Cancer Registry, encompassing male patients diagnosed with breast cancer between 2015 and 2023. A total of 470 patient records were included. We described patient and tumor characteristics using descriptive statistics. Overall survival was analyzed using Kaplan-Meier survival curves and Cox proportional hazards regression models to identify significant determinants.In our cohort of male patients with non-metastatic breast cancer, luminal subtype was the predominant tumor biology, accounting for 90% of cases. HER2-positive tumors were observed in 9% of patients, while triple-negative tumors were rare, with only four cases identified. Regarding tumor staging, 81.7% of patients were diagnosed at T1 or T2 stages. However, a substantial proportion (48.7%) presented with clinically involved lymph nodes, and 27.1% were diagnosed at UICC stage III. The five-year overall survival rate for the cohort was 73.7%. Treatment analysis revealed that 86% of patients underwent surgical intervention. Mastectomy combined with sentinel lymph node dissection was the most frequent surgical procedure, performed in 50.6% of cases. Adjuvant radiotherapy was administered to 72.8% of patients. Cox regression analysis identified age, nodal status, and surgical intervention as significant determinants of overall survival.
000303658 536__ $$0G:(DE-HGF)POF4-319H$$a319H - Addenda (POF4-319H)$$cPOF4-319H$$fPOF IV$$x0
000303658 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303658 650_7 $$2Other$$aMale breast cancer
000303658 650_7 $$2Other$$aReal-world data
000303658 650_7 $$2Other$$aSurgery
000303658 7001_ $$aDannehl, D.$$b1
000303658 7001_ $$aEndres, H.$$b2
000303658 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, L.$$b3$$udkfz
000303658 7001_ $$0P:(DE-He78)a8ce1da94e91296e574e4849cfabd230$$aHermann, S.$$b4$$udkfz
000303658 7001_ $$aHartkopf, A. D.$$b5
000303658 7001_ $$aHuwer, S.$$b6
000303658 7001_ $$aJung, L.$$b7
000303658 7001_ $$aThijssen, O.$$b8
000303658 7001_ $$aJuhasz-Böss, I.$$b9
000303658 7001_ $$aTaran, F. A.$$b10
000303658 773__ $$0PERI:(DE-600)1458450-5$$a10.1007/s00404-025-08139-8$$pnn$$tArchives of gynecology and obstetrics$$vnn$$x0003-9128$$y2025
000303658 909CO $$ooai:inrepo02.dkfz.de:303658$$pVDB
000303658 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000303658 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8ce1da94e91296e574e4849cfabd230$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000303658 9131_ $$0G:(DE-HGF)POF4-319H$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000303658 9141_ $$y2025
000303658 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-11$$wger
000303658 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-11$$wger
000303658 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bARCH GYNECOL OBSTET : 2022$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000303658 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-11
000303658 9201_ $$0I:(DE-He78)M110-20160331$$kM110$$lM110 Epidemiologisches Krebsregister BW$$x0
000303658 980__ $$ajournal
000303658 980__ $$aVDB
000303658 980__ $$aI:(DE-He78)M110-20160331
000303658 980__ $$aUNRESTRICTED